非小细胞肺癌的标靶治疗市场:KOL的洞察

本报告提供全球非小细胞肺癌的标靶治疗市场相关调查，提供市场概要，以及已通过核准治疗方法，开发平台趋势，未来预测等资讯。

目录

摘要整理

现在及未来的治疗流程

调查目的

EGFR及HER2抑制剂

• 已通过核准及开发平台的医药品
  • Tagrisso（奥希替尼、阿斯特捷利康）
  • Rybrevant（amivantamab-vmjw、Genmab/Janssen）与 Leclaza（lazertinib、Janssen）
  • Exkivity（mobocertinib，武田药）
• 正在研究药物
  • 奥莫替尼（江苏恆瑞製药）
  • ?罗替尼（江苏恆瑞製药）

抗体-药物结合物

• 核准的药品
  • Enhertz（曲妥珠单抗 deruxtecan、第一三共/阿斯特捷利康）
• 管道疗法
  • Trodelvy（sacituzumab govitecan，吉利德）和 datopotamab deruxtecan（阿斯特捷利康/第一三共）
  • Patritumab deruxtecan（第一三共）
  • Tsamitamavravtansin（赛诺菲）
  • Terisotuzumab vedotin（艾伯维）

ALK 抑制剂

• 核准的治疗方法 (7)
  • Alecensa（alectinib，罗氏）、Alunbrig（brigatinib，武田）和 Lorbrena/Lorviqua（lorlatinib，辉瑞）
• 管道疗法
  • Ensartinib（贝达製药/Xvocery）

KRAS 抑制剂

• 核准的药品 (16)
  • Lumaclas/Lumiclas（Sotorasib、安进）
  • Krazati（adagrasib，Mirati Therapeutics）
• 管道疗法
  • JDQ443（诺华）

MET抑制剂

• 核准的药品
  • Tabrecta（卡马替尼，诺华）和 Tepmetco（tepotinib，默克集团）(8)
• 管道疗法
  • 沃利替尼（阿斯特捷利康/Hutchmed）

RET抑制剂

• 核准的药品
  • Gavreto（pralsetinib，Blueprint Medicines）和 Retevmo/Retsevmo（selpercatinib，礼来）

未来治疗趋势

• 主要见解摘要

附录

新闻

Which combination strategies do KOLs say are likely to expand use of AstraZeneca's dominant EGFR TKI therapy Tagrisso? How do KOLs assess the potential of Genmab/Janssen's Rybrevant + Janssen's Leclaza in patients with EGFR-TKI resistance? Do KOLs believe the Phase III DESTINY-Lung04 study could establish Daiichi Sankyo/AstraZeneca's ADC Enhertu as a first-line therapy? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users have access to the following KOL Bulletins via the Attachments area.

• 15 Sep 2023 KOL Bulletin -- Views on Phase III ALINA data for Roche's Alecensa

• 21 Sep 2023 KOL Bulletin -- Views on Phase III FLAURA2 data for AstraZeneca's Tagrisso

Table of Contents

Executive summary (6)

Current and future treatment algorithm

Research objectives (2)

EGFR and HER2 inhibitors (46)

• Approved and pipeline drugs (31)
  • Tagrisso (osimertinib; AstraZeneca) (13)
  • Rybrevant (amivantamab-vmjw; Genmab/Janssen) and Leclaza (lazertinib; Janssen) (12)
  • Exkivity (mobocertinib; Takeda) (6)
• Pipeline drugs (15)
  • Aumolertinib (Jiangsu Hansoh Pharmaceutical) (8)
  • Pyrotinib (Jiangsu Hengrui Pharmaceuticals) (7)

Antibody-drug conjugates (31)

• Approved drugs (10)
  • Enhertu (trastuzumab deruxtecan; Daiichi Sankyo/AstraZeneca) (10)
• Pipeline therapies (21)
  • Trodelvy (sacituzumab govitecan; Gilead) and datopotamab deruxtecan (AstraZeneca/Daiichi Sankyo) (7)
  • Patritumab deruxtecan (Daiichi Sankyo) (5)
  • Tusamitamab ravtansine (Sanofi) (5)
  • Telisotuzumab vedotin (AbbVie) (4)

ALK inhibitors (12)

• Approved therapies (7)
  • Alecensa (alectinib; Roche), Alunbrig (brigatinib; Takeda) and Lorbrena/Lorviqua (lorlatinib; Pfizer) (7)
• Pipeline therapies (5)
  • Ensartinib (Betta Pharmaceuticals/Xvocery) (5)

KRAS inhibitors (21)

• Approved drugs (16)
  • Lumakras/Lumykras (sotorasib; Amgen) (10)
  • Krazati (adagrasib; Mirati Therapeutics) (6)
• Pipeline therapies (5)
  • JDQ443 (Novartis) (5)

MET inhibitors (15)

• Approved drugs (8)
  • Tabrecta (capmatinib; Novartis) and Tepmetko (tepotinib; Merck Group) (8)
• Pipeline therapies (7)
  • Savolitinib (AstraZeneca/Hutchmed) (7)

RET inhibitors (8)

• Approved drugs (8)
  • Gavreto (pralsetinib; Blueprint Medicines) and Retevmo/Retsevmo (selpercatinib; Lilly) (8)

Future treatment trends (8)

• Key insights summary (8)

Appendix (4)

• KOL details (4)
  • KOLs from the USA (1)
  • KOLs from Europe (2)

News (2)